MNU-induced mammary gland carcinogenesis: Chemopreventive and therapeutic effects of vitamin D and Seocalcitol on selected regulatory vitamin D receptor pathways

Toxicology Letters

Volumn 207, Issue 1, 2011, Pages 60-72

  Macejová, Dana ^a   Ondková, Slavomíra ^a   Jakubíková, Lucia ^a,b   Mlynarčíková, Alžbeta ^a   Scsuková, Soňa ^a   Liška, Ján ^a,c   Brtko, Július ^a  

^a INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^b Biont as   (Slovakia)

^c Faculty of Natural Sciences   (Slovakia)

Author keywords

Hydroxylase; MNU induced mammary gland tumors; Nuclear receptors; Seocalcitol (EB1089); Vitamin D

Indexed keywords

25 HYDROXYLASE; CALCIDIOL 1 MONOOXYGENASE; CELL NUCLEUS RECEPTOR; COLECALCIFEROL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUORODEOXYGLUCOSE F 18; MESSENGER RNA; METHYLNITROSOUREA; OXYGENASE; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR GAMMA; SEOCALCITOL; STEROID 24 HYDROXYLASE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER PREVENTION; CANCER SIZE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIESTRUS; DNA SEQUENCE; DRUG EFFECT; ENZYME REGULATION; ESTRADIOL BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; KIDNEY; KIDNEY FUNCTION; LIVER; LIVER FUNCTION; METESTRUS; MOLECULAR INTERACTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROESTRUS; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; CALCITRIOL; CELL TRANSFORMATION, NEOPLASTIC; CHOLECALCIFEROL; FEMALE; HISTOCYTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; MIXED FUNCTION OXYGENASES; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

RATTUS;

EID: 80053386127     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.07.029     Document Type: Article

References (57)

1. Abe-Hashimoto J., Kikuchi T., Matsumoto T., Nishii Y., Ogata E., Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res. 1993, 53:2534-2537.
2. Albertson D.G., Ylstra B., Segraves R., Collins C., Dairkee S.H., Kowbel D., Kuo W.L., Gray J.W., Pinkel D. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 2000, 25:144-146.
3. Anderson M.G., Nakane M., Ruan X., Kroeger P.E., Wu-Wong J.R. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol. 2006, 57:234-240.
4. Andrews N.C., Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acid Res. 1991, 19:2499.
5. Bareis P., Bises G., Bischof M.G., Cross H.S., Peterlik M. 25-Hydroxy-vitamin D metabolism in human colon cancer cells during tumor progression. Biochem. Biophys. Res. Commun. 2001, 285:1012-1017.
6. 3 receptor in breast cancer. Cancer Res. 1987, 47:6793-6799.
7. Bhatia V., Saini M.K., Shen X., Bi L.X., Qiu S., Weigel N.L., Falzon M. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol. Cancer Ther. 2009, 8:1787-1798.
8. Bouillon R., Bischoff-Ferrari H., Willett W. Vitamin D and health: perspectives from mice and man. J. Bone Miner. Res. 2008, 23:974-979.
9. Campbell F.C., Xu H., El-Tanani M., Crowe P., Bingham V. The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem. Pharmacol. 2010, 79:1-9.
10. Carlberg C., Bendik I., Wyss A., Meier E., Sturzenbecker L.J., Grippo J.F., Hunziker W. Two nuclear signalling pathways for vitamin D. Nature 1993, 361:657-660.
11. Colston K.W., Mackay A.G., James S.Y., Binderup L., Chander S., Coombes R.C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 1992, 44:2273-2280.
12. Colston K.W., Pirianov G., Bramm E., Hamberg K.J., Binderup L. Effects of Seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors. Breast Cancer Res. Treat. 2003, 80:303-311.
13. Dalhoff K., Dancey J., Astrup L., Skovsgaard T., Hamberg K.J., Lofts F.J., Rosmorduc O., Erlinger S., Bach Hansen J., Steward W.P., Skov T., Burcharth F., Evans T.R. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 2003, 89:252-257.
14. 3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 2000, 60:2304-2312.
15. Ethier C., Goupil D., Demers C., Hendy G.N., Gascon-Barre M. Hypocalcemia, regardless of the vitamin D status, decreases epidermal growth factor receptor density and autophosphorylation in rat livers. Endocrinology 1993, 133:780-792.
16. Fanjul A.N., Bouterfa H., Dawson M., Pfahl M. Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res. 1996, 56:1571-1577.
17. Friedrich M., Rafi L., Mitschele T., Tilgen W., Schmidt W., Reichrath J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 2003, 164:239-246.
18. Ghous Z., Akhter J., Pourgholami M.H., Morris D.L. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer Res. 2008, 28:3757-3761.
19. Gulliford T., English J., Colston K.W., Menday P., Moller S., Coombes R.C. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br. J. Cancer 1998, 78:6-13.
20. Hansen C.M., Hamberg K.J., Binderup E., Binderup L. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr. Pharm. Des. 2000, 6:803-828.
21. Hugel U., Weber L., Reichrath J., Mehls O., Klaus G. Rat growth plate chondrocytes express low levels of 25-hydroxy-1alpha-hydroxylase. J. Steroid Biochem. Mol. Biol. 2004, 89-90:143-147.
22. Jaaskelainen T., Ryhanen S., Mahonen A., DeLuca H.F., Maenpaa P.H. Mechanism of action of superactive vitamin D analogs through regulated receptor degradation. J. Cell. Biochem. 2000, 76:548-558.
23. James S.Y., Mackay A.G., Binderup L., Colston K.W. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J. Endocrinol. 1994, 141:555-563.
24. James S.Y., Mercer E., Brady M., Binderup L., Colston K.W. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol. 1998, 125:953-962.
25. Kemmis C.M., Salvador S.M., Smith K.M., Welsh J. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J. Nutr. 2006, 136:887-892.
26. Knight J.A., Wong J., Blackmore K.M., Raboud J.M., Vieth R. Vitamin D association with estradiol and progesterone in young women. Cancer Causes Control 2010, 21:479-483.
27. 3 downregulates CYP27B1 and induces CYP24A1 in colon cells. Mol. Cell. Endocrinol. 2007, 263:55-64.
28. Lemon B.D., Freedman L.P. Nuclear receptor cofactors as chromatin remodelers. Curr. Opin. Genet. Dev. 1999, 9:499-504.
29. Liska J., Macejova D., Galbavy S., Baranova M., Zlatos J., Stvrtina S., Mostbock S., Weiss R., Scheiblhofer S., Thalhamer J., Brtko J. Treatment of 1-methyl-1-nitrosourea-induced mammary tumours with immunostimulatory CpG motifs and 13-cis retinoic acid in female rats: histopathological study. Exp. Toxicol. Pathol. 2003, 55:173-179.
30. 3 analogue Seocalcitol. Biologia (Bratisl.) 2011, 66:365-369.
31. Lokeshwar B.L., Schwartz G.G., Selzer M.G., Burnstein K.L., Zhuang S.H., Block N.L., Binderup L. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol. Biomarkers Prev. 1999, 8:241-248.
32. 3 analogues in breast cancer cells. Cancer Res. 1996, 56:2789-2794.
33. 3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Mol. Cancer Ther. 2008, 7:1268-1274.
34. Luo W.J., Chen J.Y., Xu W., Zhao F., Chen Y.M., Shen X.F. Effects of vitamin D analogue EB1089 on proliferation and apoptosis of hepatic carcinoma cells. Zhonghua Yu Fang Yi Xue Za Zhi 2004, 38:415-418.
35. Ma Y., Trump D.L., Johnson C.S. Vitamin D in combination cancer treatment. J. Cancer 2010, 1:101-107.
36. Macejova D., Baranova M., Liska J., Brtko J. Expression of nuclear hormone receptors, their coregulators and type I iodothyronine 5′-deiodinase gene in mammary tissue of nonlactating and postlactating rats. Life Sci. 2005, 77:2584-2593.
37. 3 affects expression of thyroid hormone receptor alpha and deiodinase activity in liver of MNU-treated Sprague-Dawley rats. Gen. Physiol. Biophys. 2009, 28:363-370.
38. Macejova D., Radikova Z., Macho L., Liska J., Brtko J. MNU-induced carcinogenesis of rat mammary gland: effect of thyroid hormone on expression of retinoic acid receptors in tumours of mammary gland. Mol. Cell. Endocrinol. 2005, 244:47-56.
39. Marshall T.G. Vitamin D discovery outpaces FDA decision making. Bioessays 2008, 30:173-182.
40. Mathiasen I.S., Sergeev I.N., Bastholm L., Elling F., Norman A.W., Jaattela M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J. Biol. Chem. 2002, 277:30738-30745.
41. McCarthy K., Laban C., Bustin S.A., Ogunkolade W., Khalaf S., Carpenter R., Jenkins P.J. Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue. Anticancer Res. 2009, 29:155-157.
42. 3 growth response of OVCAR-3 ovarian cancer cells. Int. J. Cancer 2004, 108:367-373.
43. Milliken E.L., Zhang X., Flask C., Duerk J.L., MacDonald P.N., Keri R.A. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Lett. 2005, 229:205-215.
44. Ondkova S., Macejova D., Brtko J. Role of dihydroxyvitamin D(3) and its nuclear receptor in novel directed therapies for cancer. Gen. Physiol. Biophys. 2006, 25:339-353.
45. Parikh G., Varadinova M., Suwandhi P., Araki T., Rosenwaks Z., Poretsky L., Seto-Young D. Vitamin D regulates steroidogenesis and insulin-like growth factor binding protein-1 (IGFBP-1) production in human ovarian cells. Horm. Metab. Res. 2010, 42:754-757.
46. Pendas-Franco N., Gonzalez-Sancho J.M., Suarez Y., Aguilera O., Steinmeyer A., Gamallo C., Berciano M.T., Lafarga M., Munoz A. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007, 75:193-207.
47. 3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res. Treat. 2009, 113:31-41.
48. 3 to calcitroic acid. Eur. J. Biochem. 1999, 262:43-48.
49. Segura C., Alonso M., Fraga C., Garcia-Caballero T., Dieguez C., Perez-Fernandez R. Vitamin D receptor ontogenesis in rat liver. Histochem. Cell Biol. 1999, 112:163-167.
50. Shankar V.N., Dilworth F.J., Makin H.L., Schroeder N.J., Trafford D.J., Kissmeyer A.M., Calverley M.J., Binderup E., Jones G. Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain. Biochem. Pharmacol. 1997, 53:783-793.
51. Schmutzler C., Brtko J., Winzer R., Jakobs T.C., Meissner-Weigl J., Simon D., Goretzki P.E., Kohrle J. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int. J. Cancer 1998, 76:368-376.
52. 3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin. Cancer Res. 2003, 9:2350-2356.
53. Theodoropoulos C., Demers C., Mirshahi A., Gascon-Barre M. 1,25-Dihydroxyvitamin D(3) downregulates the rat intestinal vitamin D(3)-25-hydroxylase CYP27A. Am. J. Physiol. Endocrinol. Metab. 2001, 281:E315-E325.
54. Townsend K., Evans K.N., Campbell M.J., Colston K.W., Adams J.S., Hewison M. Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J. Steroid Biochem. Mol. Biol. 2005, 97:103-109.
55. 3 analog, EB1089. Endocrinology 1998, 139:2102-2110.
56. 3 analogues and tamoxifen. Cancer Res. 1994, 54:5711-5717.
57. Xu L., Glass C.K., Rosenfeld M.G. Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev. 1999, 9:140-147.